Abstracts tagged "Juvenile idiopathic arthritis"

Abstract Number: 0422 • ACR Convergence 2025
Clinical Outcomes of Ultrasound Guidance for Corticosteroid Injections of the Ankle and Midfoot Joints and Tendon Sheaths in Children with Juvenile Idiopathic Arthritis
Rina Ferguson¹, Xing Wang², Erin Balay-Dustrude³, Ramesh Iyer³, Natalie Rosenwasser¹, Susan Shenoi⁴ and Yongdong (Dan) Zhao⁵, ¹Seattle Children's Hospital, Seattle, WA, ²Seattle Children's Hospital, Seattle, ³University of Washington, Seattle, WA, ⁴Seattle Children's Hospital and Research Center, Mercer Island, WA, ⁵Seattle Children’s Research Institute, Redmond, WA
Background/Purpose: Intra-articular corticosteroid injections (IACI) are used to treat active ankle or midfoot inflammation in juvenile idiopathic arthritis (JIA). Ultrasound (US) can help identify the…
Abstract Number: 0403 • ACR Convergence 2025
IL-6 as a Predictor of Response to Olokizumab in Polyarticular-Course Juvenile Idiopathic Arthritis: Results of the Phase 2 Clinical Trial
Ekaterina Alexeeva¹, Tatiana Dvoryakovskaya¹, Elena Zholobova², Elizaveta Krekhova³, Valeria Matkava⁴, Rinat Raupov⁵, Daria Bukhanova⁶, Alina Egorova⁶, Sergey Grishin⁶, Mikhail Samsonov⁶, Mikhail Kostik⁷ and Irina Nikishina⁴, ¹National Medical Research Center for Children’s Health Federal State Autonomous Institution of the Russian Federation Ministry of Health and I.M. Sechenov First Moscow State Medical University (Sechenovskiy University), Moscow, Russia, ²I.M.Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia, ³National Medical Research Center for Children’s Health Federal State Autonomous Institution of the Russian Federation Ministry of Health, Moscow, Russia, ⁴V.A.Nasonova Research Institute of Rheumatology, Moscow, Russia, ⁵H.Turner National Medical Research Center for Childrens Orthopaedics and Trauma Surgery, Saint-Petersburg, Russia, ⁶R-Pharm JSC, Moscow, Russia, ⁷Saint-Petersburg State Pediatric Medical University, Saint Petersburg, Russia
Background/Purpose: Olokizumab (OKZ) is a direct interleukin-6 (IL-6) inhibitor. IL-6 is an attractive target for the treatment of pJIA. The aim of the study was…
Abstract Number: 2130 • ACR Convergence 2025
Systemic juvenile idiopathic arthritis- Fifteen-year experience from a tertiary centre at Bristol, United Kingdom
Ashwini Batchu Prithvi, Chaitra Govardhan, Bushra Aladaileh and Athimalaipet V Ramanan, Bristol Royal Hospital for Children, Bristol, United Kingdom
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is a chronic disease that results in significant morbidity and mortality in children1. Improved understanding of the pathophysiology of…
Abstract Number: 1704 • ACR Convergence 2025
Relationships between Neighborhood Disadvantage, Cumulative Social Disadvantage, and JIA Outcomes: A CARRA Registry Study
William Soulsby¹, John Boscardin², Daniel Horton³, Andrea Knight⁴, Karine Toupin-April⁵ and Emily von Scheven², ¹University of California, San Francisco, San Francisco, CA, ²UCSF, San Francisco, CA, ³Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ⁴Hospital for Sick Children, Toronto, ON, Canada, ⁵University of Ottawa, Ottawa, ON, Canada
Background/Purpose: Social determinants of health (SDOH) operate across individual, family, and community levels. We previously demonstrated that cumulative social disadvantage, comprised of individual and family-level…
Abstract Number: 0420 • ACR Convergence 2025
Long-term efficacy of intra-articular triamcinolone hexacetonide injections in juvenile idiopathic arthritis patients starting tumor necrosis factor inhibitor therapy: 48 weeks results from a randomized, open-label, blinded-assessor multicenter phase 4 trial – the MyJIA trial
Pernille Büyesen¹, Anna-Birgitte Aga¹, Vibke Lilleby¹, Maiju Pesonen¹, Marite Rygg², Ellen Nordal³, Bjørn Barstad⁴, Karin Tylleskär⁵, Helga Sanner¹, Siri Hetlevik¹, Nina Martine Sande¹, Inge Christoffer Olsen¹, Siri Lillegraven⁶, Espen Haavardsholm⁷, Athimalaipet Ramanan⁸, Oyvind Molberg⁹ and Berit Flatø¹, ¹Oslo University Hospital, Oslo, Norway, ²Department of Clinical and Molecular Medicine, NTNU - Norwegian University of Science and Technology and Department of Pediatrics, St. Olavs Hospital, Trondheim, Norway., Trondheim, Norway, ³University Hospital of North Norway, Tromsø, Nepal, ⁴Stavanger University Hospital, Stavanger, Norway, ⁵Haukeland University Hospital, Bergen, Norway, ⁶Diakonhjemmet Hospital, Oslo, Norway, ⁷Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ⁸Bristol Royal Hosp for Children, Bristol, United Kingdom, ⁹Oslo University Hospital, Oslo, Nepal
Background/Purpose: Modern therapies have improved outcomes in patients with JIA, but up to 60% of patients treated with TNF-α inhibitors (TNFi) have persisting disease activity…
Abstract Number: 0401 • ACR Convergence 2025
Longitudinal Effectiveness of Abatacept in JIA: Results From an Ongoing JIA Registry
Daniel Lovell¹, Nicolino Ruperto², Jennifer Huggins³, Ekaterina Alexeeva⁴, Colleen Correll⁵, John Bohnsack⁶, Stacey Tarvin⁷, Gabriele Simonini⁸, Thomas Griffin⁹, Andrew Zeft¹⁰, Gerd Horneff¹¹, Pierre Quartier¹², Iionka Orban¹³, Heather Walters¹⁴, Valda Stanevica¹⁵, Julisa Patel¹⁶, Adam M Huber¹⁷, Margalit Rosenkranz¹⁸, Daniel Kingsbury¹⁹, Rosie Scuccimarri²⁰, Gabriel Vega Cornejo²¹, Joost Swart²², Robert Carroll²³, Hermine Brunner¹, Tina Sherrard²⁴, Chiara Pallotti²⁵, Clara Malattia²⁶ and Alberto Martini²⁶, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Università degli Studi Milano-Bicocca, Milan, Italy, ³Cincinnati Children's Medical Center, Cincinnati, OH, ⁴National Medical Research Center for Children’s Health Federal State Autonomous Institution of the Russian Federation Ministry of Health and I.M. Sechenov First Moscow State Medical University (Sechenovskiy University), Moscow, Russia, ⁵University of Minnesota, Minneapolis, MN, ⁶University of Utah, Salt Lake City, UT, ⁷Riley Hospital for Children at Indiana University, Indianapolis, IN, ⁸Rheumatology Unit, ERN-ReCONNET center, Meyer Children's Hospital IRCCS, Firenze, Firenze, Italy, ⁹Atrium Health Levine Children’s Hospital, Charlotte, NC, ¹⁰Cleveland Clinic, Cleveland, OH, ¹¹Asklepios Klinik, Hamburg, Germany, ¹²Hôpital Necker-Enfants Malades, Paris, France, ¹³Department of Rheumatology and Clinical Immunology of Semmelweis University, Budapest, Hungary, ¹⁴Northwell, New Hyde Park, NY, ¹⁵Riga Stradiņš University, Riga, Latvia, ¹⁶Children’s Hospital of Georgia, Augusta University, Augusta, GA, ¹⁷IWK Grace Health Centre, Halifax, NS, Canada, ¹⁸University of Pittsburgh, Pittsburgh, PA, ¹⁹Randall Children’s Hospital at Legacy Emanuel, Portland, OR, ²⁰McGill University Health Centre, Montreal, QC, Canada, ²¹Clinica de reumatología Guadalajara, Guadalajara, Jalisco, Mexico, ²²Wilhelmina Children's Hospital / UMC Utrecht, Utrecht, Utrecht, Netherlands, ²³Bristol Myers Squibb, London, United Kingdom, ²⁴Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²⁵Istituto G. Gaslini, Servizio di Sperimentazioni Cliniche Pediatriche, Genova, Italy, ²⁶Istituto G. Gaslini Pediatria II Reumatologia and University of Genova, Genova, Italy
Background/Purpose: Abatacept is a selective T-cell co-stimulation modulator approved for use in JIA. Efficacy and safety of abatacept in patients (pts) with JIA have been…
Abstract Number: 2029 • ACR Convergence 2025
Characteristics of a Historical Cohort of Adult Patients with Juvenile Idiopathic Arthritis
Francina salabert-Carreras¹, Raquel Ugena-García², Cristina Rocamora-Gisbert³, Cristina Calomarde-Gómez², Clara Churtichaga Domenech¹, Judith Vidal ripoll¹, LOURDES MATEO SORIA⁴, Laia Gifre-Sala¹, Maria Aparicio³, Susana Holgado⁵, Águeda Prior Español¹, Anne Riveros frutos³, Ivette Casafont-Solé², Eva Forcadell Pirretas¹, Anna Pujol Manresa¹, Judit Font-Urgelles², Melania Martínez-Morillo¹ and Annika Nack³, ¹Hospital Germans Trias i Pujol, Barcelona, ²Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ³Hospital Germans Trias i Pujol, Barcelona, Spain, ⁴HOSPITAL GERMANS TRIAS I PUJOL, BADALONA, Spain, ⁵Hospital Germans Trias i Pujol, Barcelona, Catalonia, Spain
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in childhood. Up to one-third of patients experience disease flares in adulthood, with…
Abstract Number: 1654 • ACR Convergence 2025
A Dual Inhibitor of TAK1 and MAP4K2, NG25, Suppresses Cytokine-Driven Inflammation in Juvenile Idiopathic Arthritis Synovial Fibroblasts
Meena Afroze Shanta¹ and Salahuddin Ahmed², ¹College of Pharmacy and Pharmaceutical Science, Washington State University, Spokane, WA, ²Washington State University, Spokane, WA
Background/Purpose: Chronic synovitis is a hallmark of juvenile idiopathic arthritis (JIA), and synovial fibroblasts are major perpetrators of inflammation and tissue destruction. Thus, we tested…
Abstract Number: 0419 • ACR Convergence 2025
Ultrasound-Guided Synovial Biopsy in Children and Adolescents with Juvenile Arthritis: Initial Results
Patricia Vega-Fernandez¹, Kelly Rogers², Megan Quinlan-Waters³, Sheila Angeles-Han², Alexei Grom¹, Daniel Lovell¹, Jennifer Huggins⁴, Ekemini Ogbu¹, Amy Cassedy⁵, Sara Szabo¹, Tracy Ting¹, Grant Schulert¹, McKenzie Vater⁶, Hermine Brunner¹, Jackeline Rodriguez-Smith¹ and Katelyn Banschbach⁷, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Cincinnati Children's Hospital, Cincinnati, OH, ³Cincinnati Children's Hospital Medical Center, CCHMC, ⁴Cincinnati Children's Medical Center, Cincinnati, OH, ⁵Cincinnati Children's hospital medical center, cincinnati, OH, ⁶Cincinnati Children's Hospital Medical Center, Fort Thomas, KY, ⁷cincinnati Children's hospital, Villa Hills, KY
Background/Purpose: Ultrasound-guided synovial biopsy (USGSB) has been recently implemented for clinical and research purposes in adults with inflammatory arthritis. The current use of USGSB in…
Abstract Number: 0400 • ACR Convergence 2025
Recent Antibiotic Exposure and Response to Treatment of Juvenile Idiopathic Arthritis
Daniel Horton¹, Charu Verma², Sanika Rege², Alicia Iizuka², Matthew Iozzio³, Dawn Koffman³, Stephen Crystal⁴, Amy Davidow⁵, Tobias Gerhard², Lauren Parlett⁶, Carlos Rose⁷ and Brian Strom⁸, ¹Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ²Rutgers Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research, Rutgers University, New Brunswick, NJ, USA, New Brunswick, NJ, ³Rutgers Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research, Rutgers University, New Brunswick, NJ, USA, New Brunswick, ⁴Rutgers Center for Health Services Research, Institute for Health, Health Care Policy and Aging Research, New Brunswick, NJ, ⁵New Jersey Medical School, Newark, NJ, ⁶Carelon Research, Inc, Wilmington, DE, ⁷Thomas Jefferson University, Wilmington, DE, ⁸Rutgers Biomedical and Health Sciences, New Brunswick
Background/Purpose: Juvenile idiopathic arthritis (JIA), the most common pediatric rheumatic disease, has been tied to microbiome disruption (dysbiosis). Dysbiosis in adults with arthritis affects response…
Abstract Number: 1989 • ACR Convergence 2025
Moving Out of the Kid’s Rheum: Transitioning Young Adult Patients from Pediatric to Adult Rheumatology Practices
Victoria Koenigsberger¹, Madeleine Ward², Meghan Geary³ and Ali Yalcindag⁴, ¹The Warren Alpert Medical School of Brown University, Providence, RI, ²The Warren Alpert Medical School of Brown University, Division of Medicine-Pediatrics, Providence, ³The Warren Alpert Medical School of Brown University, Division of General Internal Medicine, Providence, ⁴The Warren Alpert Medical School of Brown University, Division of Rheumatology, Department of Pediatrics, Milton, MA
Background/Purpose: Young adults with childhood-onset rheumatic conditions encounter challenges and barriers to care when transitioning to an adult rheumatologist. At this Pediatric Rheumatology Clinic, patients…
Abstract Number: 1304 • ACR Convergence 2025
The role of PET/CT in evaluating rheumatologic conditions in children with fever of unknown origin – a multicenter study
Neta Berlak¹, Lydia Christodoulou², Gil Amarilyo³, Oded Scheuerman⁴, Irit Tirosh⁵, Eyal Kristal⁶, Ester Forer⁷, Amit Carmi⁸, Alon Kalter⁹ and Yoel Levinsky¹⁰, ¹Schneider children's medical center of Israel, Tel Aviv, Israel, ²Tel Hashomer, Periatric rheumatology unit, Tel Aviv, Israel, ³Schneider Children's Medical Center of Israel, Kibbutz Maggal, Israel, ⁴schneider children's meidcal center of Israel, Petah tikva, Israel, ⁵Tel Aviv universty, Ramat Gan, Israel, ⁶Soroka medical center Beer Sheva, Beer Sheva, Israel, ⁷Soroka medical center, Beer Sheva, Israel, ⁸Schneider children's meidcal center of Israel, Tel Aviv, Israel, ⁹Schneider children's medical center of ISrael, Petah Tikva, Israel, ¹⁰Schneider Children's Medical Cenetr of Israel, Tel Aviv University, JERUSALEM, Israel
Background/Purpose: Fever of Unknown Origin (FUO) is a relatively common clinical challenge that is frequently referred for evaluation by pediatric rheumatologists. In many cases, it…
Abstract Number: 0418 • ACR Convergence 2025
Evaluation of Disease Activity in the Knee Joint Through Clinical, Radiologic, Synovial Fluid and Histopathologic Measurements of Inflammation in Children with Juvenile Idiopathic Arthritis
Patricia Vega-Fernandez¹, Kelly Rogers², Alyssa Sproles², Sherry Thornton¹, Lexi Auld³, Jackeline Rodriguez-Smith¹, Ekemini Ogbu¹, Kara Murphy Schmidt⁴, McKenzie Vater⁵, Katelyn Banschbach⁶, Grant Schulert¹, Alexei Grom¹, Sheila Angeles-Han², Hermine Brunner¹, Jennifer Huggins⁷, Daniel Lovell¹, Amy Cassedy⁸, Yuriy Baglaenko², Tracy Ting¹ and Sara Szabo¹, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Cincinnati Children's Hospital, Cincinnati, OH, ³Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Cincinnati, OH, ⁴Cincinnati Children’s Hospital Medical Center, Louisville, KY, ⁵Cincinnati Children's Hospital Medical Center, Fort Thomas, KY, ⁶cincinnati Children's hospital, Villa Hills, KY, ⁷Cincinnati Children's Medical Center, Cincinnati, OH, ⁸Cincinnati Children's hospital medical center, cincinnati, OH
Background/Purpose: Clinical, radiologic and biomarker data are measurements used in the assessment of juvenile idiopathic arthritis (JIA) disease activity. The development of ultrasound-guided synovial biopsy…
Abstract Number: 0399 • ACR Convergence 2025
External Validation of Claims-based Algorithms for Newly Diagnosed Juvenile Idiopathic Arthritis
Daniel Horton¹, Lauren Parlett², Yuyang Zhu³, Sanika Rege⁴, Patricia Hoffman⁵, Daniel Reiff⁶, Sarah McGuire⁷, Sonia Pothraj⁸, Cynthia Salvant⁹, Lakshmi Moorthy¹, Cecilia Huang⁴, Dawn Koffman⁴, Matthew Iozzio³, Alicia Iizuka⁴, Kevin Schott², Stephen Crystal¹⁰, Amy Davidow¹¹, Tobias Gerhard⁴, Kevin Haynes¹², Brian Strom¹³, Daniel Beachler² and Carlos Rose¹⁴, ¹Department of Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ²Carelon Research, Inc, Wilmington, DE, ³Rutgers Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research, Rutgers University, New Brunswick, NJ, USA, New Brunswick, ⁴Rutgers Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research, Rutgers University, New Brunswick, NJ, USA, New Brunswick, NJ, ⁵Hospital for Special Surgery, New York, NY, ⁶Boys Town National Research Hospital, Boys Town, ⁷Department of Obstetrics and Gynecology, Cooper Medical School, Camden, Camden, NJ, ⁸Washingtonville Pediatrics, Washingtonville, NY, ⁹Albany Medical Center, Albany, NY, ¹⁰Rutgers Center for Health Services Research, Institute for Health, Health Care Policy and Aging Research, New Brunswick, NJ, ¹¹New Jersey Medical School, Newark, NJ, ¹²Janssen Research & Development, Titusville, NJ, ¹³Rutgers Biomedical and Health Sciences, New Brunswick, ¹⁴Thomas Jefferson University, Wilmington, DE
Background/Purpose: Administrative claims databases enable research in large populations with JIA. We previously showed that machine learning (ML)-based algorithms accurately identify new JIA diagnoses within…
Abstract Number: L09 • ACR Convergence 2024
Efficacy and Safety of Tofacitinib in Patients with Active Systemic Juvenile Idiopathic Arthritis
Hermine Brunner¹, Caifeng Li², Kogie Chinniah³, Yosef Uziel⁴, Olga Synoverska⁵, Sujata Sawhney⁶, Inmaculada Calvo Penades⁷, Ingrid Clara Louw⁸, Meiping Lu⁹, Pooja Nikunj Patel¹⁰, Pamela F. Weiss¹¹, Cheng Chang¹², Ivana Vranic¹³, Shixue Liu¹⁴, Annette Diehl¹⁵, Jose L. Rivas¹⁶, Carol A. Connell¹⁷, Gary G. Koch¹⁸, Alberto Martini¹⁹, Daniel J. Lovell¹, Nicolino Ruperto²⁰ and the PRINTO and PRCSG investigators, ¹Cincinnati Children’s Hospital Medical Center, and University of Cincinnati, Cincinnati, OH, ²Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Bejing, China, ³Department of Paediatrics and Child Health, University of Kwa-Zulu, and Enhancing Care Foundation, Durban, South Africa, ⁴Pedriatric Rheumatology Unit, Department of Pediatrics, Meir Medical Center and Israel Tel Aviv University School of Medicine, Kfar Saba, Israel, ⁵Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine, ⁶Sir Ganga Ram Hospital, New Delhi, India, ⁷Hospital Universitario y Politécnico La Fe, Valencia, Spain, ⁸Panorama Medical Centre, Cape Town, South Africa, ⁹Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China, ¹⁰Ann & Robert H. Lurie Children’s Hospital of Chicago; Northwestern University School of Medicine, Chicago, IL, ¹¹Division of Rheumatology, Children's Hospital of Philadelphia, and University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ¹²Pfizer Inc, New York, NY, ¹³Pfizer Ltd, Tadworth, United Kingdom, ¹⁴Pfizer Inc, Shanghai, China, ¹⁵Pfizer Inc, Collegeville, PA, ¹⁶Pfizer SLU, Madrid, Spain, ¹⁷Pfizer Inc, Groton, CT, ¹⁸University of North Carolina at Chapel Hill, Chapel Hill, NC, ¹⁹University of Genoa, Genoa, Italy, ²⁰Università Milano Bicocca, Milano, and IRCCS Fondazione San Gerardo dei Tintori, Monza, Italy
Background/Purpose: Tofacitinib (TOF) has been shown to be efficacious in the treatment of polyarticular course JIA, including systemic JIA (sJIA) without active systemic features. Here…

« Previous Page
1
…
3
4
5
6
7
…
25
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].